Analysis of clinical characteristics of macrophage capping protein (CAPG) gene expressed in glioma based on TCGA data and clinical experiments

Fu,Qiang; Shaya,Mahati; Li,Shaoshan; Kugeluke,Yalikun; Dilimulati,Yisireyili; Liu,Bo; Zhou,Qingjiu

doi:10.3892/ol.2019.10396

Analysis of clinical characteristics of macrophage capping protein (CAPG) gene expressed in glioma based on TCGA data and clinical experiments

Authors:
- Qiang Fu
- Mahati Shaya
- Shaoshan Li
- Yalikun Kugeluke
- Yisireyili Dilimulati
- Bo Liu
- Qingjiu Zhou
View Affiliations

Affiliations: Department of Neurosurgery, First Affiliated Hospital of Xinjiang Medical University (XJMU), Urumqi, Xinjiang 830011, P.R. China, Department of Tumor Center, First Affiliated Hospital of Xinjiang Medical University (XJMU), Urumqi, Xinjiang 830011, P.R. China
Published online on: May 23, 2019 https://doi.org/10.3892/ol.2019.10396
Pages: 1344-1350
Copyright: © Fu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Macrophage capping protein (CAPG) genes were investigated based on The Cancer Genome Atlas (TCGA) database and clinical experiments. Glioblastoma (GBM) genes expression profiling chip of 529 disease samples and 10 normal samples selected from TCGA database were used for analysis, 25 brain glioma tissue samples and 15 normal brain tissues were collected in the Department of Neurosurgery of the First Affiliated Hospital of Xinjiang Medical University in China from 2016 to 2017 to analyze CAPG genes. TCGA results showed that the expression level of CAPG genes in GBM was higher than that in normal tissues, and the expression level of men, aged over 46 years and high grade gliomas in pathological stages was higher than that of women, aged ≤46 and low grade gliomas in pathological stages, and the survival time of high expression was shorter than that of low expression. The expression level of CAPG in glioma tissues was higher than that in normal tissues, and the expression level of CAPG in males was higher than that in females, as males had lymphatic transfer and low differentiation compared with females, but the expression level was not related to age. Survival analysis showed that higher expression level indicated shorter survival time, they were positively correlated. The expression of CAPG in glioma is high, and it is highly expressed with the severity of the disease, and it is also obviously related to the prognosis. Therefore, CAPG could be used as a biomarker for pathological grade and prognosis in glioma. However, the related studies are not consistent on the expression of different sex and ages, so further study is needed.

View Figures

View References

1	Oh J, Kim Y, Che L, Kim JB, Chang GE, Cheong E, Kang SG and Ha Y: Regulation of cAMP and GSK3 signaling pathways contributes to the neuronal conversion of glioma. PLoS One. 12:e01788812017. View Article : Google Scholar : PubMed/NCBI
2	Yu X, Sun NR, Jang HT, Guo SW and Lian MX: Associations between EGFR gene polymorphisms and susceptibility to glioma: a systematic review and meta-analysis from GWAS and case-control studies. Oncotarget. 8:86877–86885. 2017.PubMed/NCBI
3	Zhao P, Chen A, Qi Q, Zhou W, Feng Z, Wang J, Yang N, Li X, Wang J, Huang Q, et al: Impact of VEGFA polymorphisms on glioma risk in Chinese. Oncotarget. 8:83712–83722. 2017.PubMed/NCBI
4	Gao L, Chen B, Li J, Yang F, Cen X, Liao Z and Long X: Wnt/β-catenin signaling pathway inhibits the proliferation and apoptosis of U87 glioma cells via different mechanisms. PLoS One. 12:e01813462017. View Article : Google Scholar : PubMed/NCBI
5	Abdul AURM, De Silva B and Gary RK: The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of β-catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 7:72018. View Article : Google Scholar
6	Biau J, Chautard E, De Schlichting E, Dupic G, Pereira B, Fogli A, Müller-Barthélémy M, Dalloz P, Khalil T, Dillies AF, et al: Radiotherapy plus temozolomide in elderly patients with glioblastoma: A ‘real-life’ report. Radiat Oncol. 12:1972017. View Article : Google Scholar : PubMed/NCBI
7	Chen Q, Ye L, Fan J, Zhang X, Wang H, Liao S, Song P, Wang Z, Wang S, Li Y, et al: Autophagy suppression potentiates the anti-glioblastoma effect of asparaginase in vitro and in vivo. Oncotarget. 8:91052–91066. 2017.PubMed/NCBI
8	Andronesi OC, Esmaeili M, Borra RJH, Emblem K, Gerstner ER, Pinho MC, Plotkin SR, Chi AS, Eichler AF, Dietrich J, et al: Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol. Jun 12–2017.(Epub ahead of print). doi: 10.1038/s41698-017-0020-3. View Article : Google Scholar : PubMed/NCBI
9	Costa RB, Costa R, Kaplan J, Cruz MR, Shah H, Matsangou M and Carneiro B: A rare case of glioblastoma multiforme with osseous metastases. Case Rep Oncol Med. 2017:29383192017.PubMed/NCBI
10	Hays EM, Duan W and Shigdar S: Aptamers and glioblastoma: Their potential use for imaging and therapeutic applications. Int J Mol Sci. 18:182017. View Article : Google Scholar
11	Van den Abbeele A, De Corte V, Van Impe K, Bruyneel E, Boucherie C, Bracke M, Vandekerckhove J and Gettemans J: Downregulation of gelsolin family proteins counteracts cancer cell invasion in vitro. Cancer Lett. 255:57–70. 2007. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Seifabadi S, Vaseghi G, Javanmard SH, Omidi E, Tajadini M and Zarrin B: The cytotoxic effect of memantine and its effect on cytoskeletal proteins expression in metastatic breast cancer cell line. Iran J Basic Med Sci. 20:41–45. 2017.PubMed/NCBI
14	Vitali E, Boemi I, Rosso L, Cambiaghi V, Novellis P, Mantovani G, Spada A, Alloisio M, Veronesi G, Ferrero S, et al: FLNA is implicated in pulmonary neuroendocrine tumors aggressiveness and progression. Oncotarget. 8:77330–77340. 2017. View Article : Google Scholar : PubMed/NCBI
15	Glaser J, Neumann MH, Mei Q, Betz B, Seier N, Beyer I, Fehm T, Neubauer H, Niederacher D and Fleisch MC: Macrophage capping protein CapG is a putative oncogene involved in migration and invasiveness in ovarian carcinoma. BioMed Res Int. 2014:3798472014. View Article : Google Scholar : PubMed/NCBI
16	Aevermann BD, Pickett BE, Kumar S, Klem EB, Agnihothram S, Askovich PS, Bankhead A III, Bolles M, Carter V, Chang J, et al: A comprehensive collection of systems biology data characterizing the host response to viral infection. Sci Data. 1:1400332014. View Article : Google Scholar : PubMed/NCBI
17	Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA and McGlynn KA: Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 54:463–471. 2011. View Article : Google Scholar : PubMed/NCBI
18	Tomczak K, Czerwińska P and Wiznerowicz M: The Cancer Genome Atlas (TCGA): An immeasurable source of knowledge. Contemp Oncol (Pozn) 19 (1A). A68–A77. 2015.
19	Zhu WY, Hunag YY, Liu XG, He JY, Chen DD, Zeng F, Zhou JH and Zhang YK: Prognostic evaluation of CapG, gelsolin, P-gp, GSTP1, and Topo-II proteins in non-small cell lung cancer. Anat Rec (Hoboken). 295:208–214. 2012. View Article : Google Scholar : PubMed/NCBI
20	Tonack S, Patel S, Jalali M, Nedjadi T, Jenkins RE, Goldring C, Neoptolemos J and Costello E: Tetracycline-inducible protein expression in pancreatic cancer cells: Effects of CapG overexpression. World J Gastroenterol. 17:1947–1960. 2011. View Article : Google Scholar : PubMed/NCBI
21	Van Impe K, Bethuyne J, Cool S, Impens F, Ruano-Gallego D, De Wever O, Vanloo B, Van Troys M, Lambein K, Boucherie C, et al: A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis. Breast Cancer Res. 15:R1162013. View Article : Google Scholar : PubMed/NCBI
22	Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE, et al: CAPG and GIPC1: Breast cancer biomarkers for bone metastasis development and treatment. J Natl Cancer Inst. 108:1082016. View Article : Google Scholar
23	Li BK, Guo K, Li CY, Li HL, Zhao PP, Chen K and Liu CX: Influence of suppression of CapG gene expression by siRNA on the growth and metastasis of human prostate cancer cells. Genet Mol Res. 14:15769–15778. 2015. View Article : Google Scholar : PubMed/NCBI
24	Xiang G: Relationship between macrophage capping protein and gastric cancer cell's proliferation and migration ability. Beijing Da Xue Xue Bao Yi Xue Ban. 49:489–494. 2017.(In Chinese). PubMed/NCBI
25	Ichikawa H, Kanda T, Kosugi S, Kawachi Y, Sasaki H, Wakai T and Kondo T: Laser microdissection and two-dimensional difference gel electrophoresis reveal the role of a novel macrophage-capping protein in lymph node metastasis in gastric cancer. J Proteome Res. 12:3780–3791. 2013. View Article : Google Scholar : PubMed/NCBI
26	Xing W and Zeng C: An integrated transcriptomic and computational analysis for biomarker identification in human glioma. Tumour Biol. 37:7185–7192. 2016. View Article : Google Scholar : PubMed/NCBI
27	Yun DP, Wang YQ, Meng DL, Ji YY, Chen JX, Chen HY and Lu DR: Actin-capping protein CapG is associated with prognosis, proliferation and metastasis in human glioma. Oncol Rep. 39:1011–1022. 2018.PubMed/NCBI